This study focuses on patients with post-resuscitation syndrome, a condition that occurs after cardiac arrest when the heart has been restarted but patients experience blood pressure problems. The study examines the effectiveness of two medications: hydrocortisone (a steroid hormone) and argipressin (also known as vasopressin, a hormone that helps control blood pressure) compared to placebo in improving survival and brain function recovery.
The research aims to determine if using these medications together leads to better outcomes for patients who have survived cardiac arrest but are experiencing circulatory problems. The medications are given through intravenous methods – either as an injection or continuous infusion. Hydrocortisone is administered at doses up to 200 mg per day, while argipressin is given through continuous infusion for up to three days.
During the study, patients receive either the combination of both active medications or their matching placebos. The treatment continues for up to seven days for hydrocortisone and three days for argipressin. Patients’ recovery is monitored for 30 days after treatment, with special attention to their brain function and overall survival. The medications are administered along with standard medical care that all patients receive in the intensive care unit.
France 
